Bionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM
May 12 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome
mapping (OGM) solutions on the Saphyr® system and provider of
NxClinical™ software, the leading solution for visualization,
interpretation and reporting of genomic data, today announced the
publication of an evaluation of OGM from The First Affiliated
Hospital of Zhengzhou, the largest hospital in Central China,
highlighting the utility of OGM for structural variant analysis,
including in a workflow for preimplantation genetic testing.
In this study, researchers, led by Dr. Xiangdong Kong, evaluated
the use of OGM to detect chromosome balanced translocations and
compared results to a variety of methods, including karyotype
analysis, FISH, and CNV-seq. Balanced reciprocal translocations are
one of the most common chromosomal abnormalities and may lead to
infertility, recurrent pregnancy loss, or genetic defects. Analysis
of this abnormality may be helpful in the screening and analysis of
embryos prior to implantation, as part of fertility treatment. The
paper suggests a need for new methods to complement existing
analysis techniques, such as karyotype and FISH, which are
described as time consuming and relatively low-resolution, and
next generation sequencing (NGS) which can enable copy number
variation (CNV) analyses at the whole genome level but cannot be
used to detect chromosomal translocations or inversions. The
authors demonstrated that OGM performed well in the analysis of
these variants, which led them to suggest that OGM could be used as
part of the workflow to detect chromosomal abnormalities at a
higher resolution.
“We believe this paper highlights the growing validation of OGM
in different applications for clinical research in cytogenetics.
The work by Dr. Kong and his team at Zhengzhou University further
extends this validation and highlights the utility of OGM.
Incorporating OGM data in the analysis of embryos prior to
implantation is innovative and the approach could be part of a
solution for recurrent pregnancy loss, which represents an area of
unmet need globally,” commented Erik Holmlin, PhD, president
and chief executive officer of Bionano Genomics.
The paper is available at:
Evaluation of optical genome mapping for detecting chromosomal
translocation in clinical cytogenetics - Dai - - Molecular Genetics
& Genomic Medicine - Wiley Online Library
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which
integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “could,” “suggest,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the ability and utility of OGM and the Saphyr® system to detect
chromosome balanced translocations in preimplantation embryos and
the potential for OGM to become part of workflow analyses to detect
chromosomal abnormalities. Each of these forward-looking statements
involves risks and uncertainties. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive technologies or
improvements in existing technologies; failure of future study
results to support those demonstrated in the paper referenced in
this press release; changes in our strategic and commercial plans;
our ability to obtain sufficient financing to fund our strategic
plans and commercialization efforts; the ability of medical and
research institutions to obtain funding to support adoption or
continued use of our technologies; and the risks and uncertainties
associated with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2021 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024